期刊文献+

初诊2型糖尿病患者采取安立泽加二甲双胍治疗的效果分析 被引量:3

在线阅读 下载PDF
导出
摘要 目的探讨初诊2型糖尿病患者采取安立泽加二甲双胍进行治疗的有效性与安全性。方法以2015年1—12月该院收治的初诊为2型糖尿病的80例患者为研究对象,随机将入选病例均分为两组。实验组40例,患者以安立泽联合二甲双胍进行治疗;对照组40例,患者以格列美脲联合二甲双胍进行治疗。统计治疗期间患者用药不良反应,观察两组患者治疗前后血糖水平、糖化血红蛋白值及胰岛素相关指标。结果实验组治疗后FBG(6.0±0.4)mmol/L,2h PG(7.9±1.3)mmol/L,HbA1c(6.3±0.7)%,空腹胰岛素水平(9.4±1.8)μU/ml,HOMA-IR(2.9±0.5),各项指标均优于对照组,差异有统计学意义(P<0.05)。实验组用药不良反应发生率(2.5%)与对照组相(5.0%)比差异无统计学意义(P>0.05)。结论以安立泽联合二甲双胍治疗初诊2型糖尿病患者,不良反应少,降糖效果明显,应用安全有效,值得临床推广。
作者 傅欢 王丽云
出处 《糖尿病新世界》 2016年第19期13-14,共2页 Diabetes New World Magazine
  • 相关文献

参考文献8

二级参考文献79

  • 1宋燕庆.二甲双胍联合沙格列汀与二甲双胍单药治疗2型糖尿病疗效比较[J].兵团医学,2013(4):18-19. 被引量:2
  • 2Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med, 2008, 359 : 1577-1589.
  • 3Ray KK, Seshasai SR, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcmnes and death in pa- tients with diabetes mellitus: a recta-analysis of randomised con- trolled trials. Lancet, 2009, 373: 1765-1772.
  • 4Control Group, Turnbull FM, Abraira C, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia, 2009, 52: 2288-2298.
  • 5IDF Clinical Guidelines Task Force. Global Guideline for Type 2 Diabetes: recommendations for standard, comprehensive, and minimal care. Diabet Med, 2006,23:579-593.
  • 6Ying W, Pan CY, Tou C, et al. Efficacy and safety of saxaglip- tin added to metformin in Asian people with type 2 diabetes: a randomized controlled trial. Diabetes Res Clin Pract, 2011, 94: 217-224.
  • 7Reasner C, Olansky L, Seek TL, et al. The effect of initial ther- apy with the fixed-dose combination of sitagliptin and metformin compared with mefformin monotherapy in patients with type 2 dia- betes mellitus. Diabetes Obes Metab, 2011, 13:644-652.
  • 8DeFronzo RA, Hissa MN, Garber AJ, et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately conttrolled type 2 diabetes with metformin alone. Diabetes Care,2009,32 : 1649-1655.
  • 9Nauck MA, Ellis GC, Fleck PR, et al. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a muhicentre, radomised, double- blind, placebo-controlled study. Int J Clin Pratt, 2009, 63: 46-55.
  • 10Rizzo MR, Barbieri M, Maffella R,et al. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctua- tions in patients with type 2 diabetes: role of dipeptidyl pepti- dase-lg inhibition. Diabetes Care, 2012, 35:2076-2082.

共引文献229

同被引文献11

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部